Part B exposure

HHS Secretary Alex Azar's proposed changes to Medicare Part B have put at least four large biopharmas at risk of substantial U.S. revenue losses. But the lack of market reaction and the views of VCs interviewed by BioCentury suggest stakeholders are skeptical the proposed modifications will become a reality.

On Oct. 25, the Trump administration proposed three major changes to the reimbursement system for drugs covered under Medicare Part B, which include products that are infused or injected under a physician’s supervision...